Skip to main content

Activating the NLRP3 Inflammasome Using the Amyloidogenic Peptide IAPP

  • Protocol
  • First Online:
The Inflammasome

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1040))

Abstract

In addition to several other extracellular substances, phagocytosis of amyloid-forming peptides can perturb cellular homeostasis, leading to activation of the cytoplasmic innate immune receptor NLRP3. Once triggered, NLRP3 forms an inflammasome complex that ultimately cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms. Here we describe a protocol by which one type of amyloidogenic peptide, islet amyloid polypeptide (IAPP, otherwise known as amylin) can be prepared and used to stimulate myeloid cells in vitro to engage the NLRP3 inflammasome. Methods for measuring the ensuing inflammasome activation are also described. Although initially soluble, IAPP monomers rapidly aggregate in solution to form oligomers and subsequently insoluble amyloid fibrils. More work is required to examine how this transition influences inflammasome activation for different types of amyloid. The course of amyloid formation and corresponding inflammatory capacity of these pre-fibrillar species following uptake also requires further examination, and we hope that our protocols are useful in these endeavors. While these protocols are restricted to examination of synthetic IAPP, isolation of IAPP aggregates from human and transgenic mouse pancreas will be required to definitively determine the proinflammatory effects of endogenous IAPP oligomers and fibrils.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tukel C, Wilson RP, Nishimori JH, Pezeshki M, Chromy BA, Baumler AJ (2009) Responses to amyloids of microbial and host origin are mediated through toll-like receptor 2. Cell Host Microbe 6(1):45–53. doi:10.1016/j.chom.2009.05.020, doi:S1931-3128(09)00213-3 [pii]

    Article  PubMed  CAS  Google Scholar 

  2. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155–161. doi:10.1038/ni.1836, doi:ni.1836 [pii]

    Article  PubMed  CAS  Google Scholar 

  3. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 187(1):64–73. doi:10.4049/jimmunol.1100500, doi:jimmunol.1100500 [pii]

    Article  PubMed  CAS  Google Scholar 

  4. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9(8):857–865. doi:10.1038/ni.1636, doi:ni.1636 [pii]

    Article  PubMed  CAS  Google Scholar 

  5. Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, Wolff H, Kovanen PT, Matikainen S, Eklund KK (2011) Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol 186(11):6119–6128. doi:10.4049/jimmunol.1002843, doi:jimmunol.1002843 [pii]

    Article  PubMed  CAS  Google Scholar 

  6. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nunez G, Yodoi J, Kahn SE, Lavelle EC, O’Neill LA (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11(10):897–904. doi:10.1038/ni.1935, doi:ni.1935 [pii]

    Article  PubMed  CAS  Google Scholar 

  7. Westwell-Roper C, Dai DL, Soukhatcheva G, Potter KJ, van Rooijen N, Ehses JA, Verchere CB (2011) IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol. doi:10.4049/jimmunol.1002854

    PubMed  Google Scholar 

  8. Masters SL, O’Neill LA (2011) Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol Med 17(5):276–282. doi:10.1016/j.molmed.2011.01.005

    Article  PubMed  CAS  Google Scholar 

  9. Kahn SE, D’Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39(5):634–638

    Article  PubMed  CAS  Google Scholar 

  10. Westermark P, Wernstedt C, Wilander E, Sletten K (1986) A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140(3):827–831

    Article  PubMed  CAS  Google Scholar 

  11. Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77(2):91–94

    PubMed  CAS  Google Scholar 

  12. Bell ET (1959) Hyalinization of the islets of Langerhans in nondiabetic individuals. Am J Pathol 35(4):801–805

    PubMed  CAS  Google Scholar 

  13. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Kahn SE (2010) Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53(6):1046–1056. doi:10.1007/s00125-010-1671-6

    Article  PubMed  CAS  Google Scholar 

  14. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (5618):486–489. doi:10.1126/science.1079469300/5618/486 [pii]

    Google Scholar 

  15. Park K, Verchere CB (2001) Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. J Biol Chem 276(20):16611–16616. doi:10.1074/jbc.M008423200 M008423200 [pii]

    Google Scholar 

  16. Kudva YC, Mueske C, Butler PC, Eberhardt NL (1998) A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. Biochem J 331(Pt 3):809–813

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Ben A. Croker for initially optimizing the IL-18 ELISA protocol. S.L.M. is supported by a fellowship from the National Health and Medical Research Council of Australia (516783). C.W.R. is supported by a Vanier Canada Graduate Scholarship and C.B.V. by grants from the Canadian Institutes of Health Research (MOP-14862) and 20R66631 and the Canadian Diabetes Association (OG-3-11-3413-CV).

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+business media, New York

About this protocol

Cite this protocol

Westwell-Roper, C., Dunne, A., Kim, M.L., Verchere, C.B., Masters, S.L. (2013). Activating the NLRP3 Inflammasome Using the Amyloidogenic Peptide IAPP. In: De Nardo, C., Latz, E. (eds) The Inflammasome. Methods in Molecular Biology, vol 1040. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-523-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-523-1_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-522-4

  • Online ISBN: 978-1-62703-523-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics